Selected research
Industry Research
Osteoporosis Injections Industry Research Report 2026
Market perspective
The global Osteoporosis Injections market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Osteoporosis Injections is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Osteoporosis Injections is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Osteoporosis Injections is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Osteoporosis Injections include Alvogen, Amgen, Asahi Kasei Pharma, Eli Lilly, Novartis, Pfizer, Pharmanovia, Radius Health and Chengdu Easton Biopharmaceuticals, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Osteoporosis Injections market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Osteoporosis Injections Market by Company
Alvogen
Amgen
Asahi Kasei Pharma
Eli Lilly
Novartis
Pfizer
Pharmanovia
Radius Health
Chengdu Easton Biopharmaceuticals
Hunan Fangsheng Pharmaceutical
Qilu Pharmaceutical
Shanghai United Cell Biotechnology
Shenzhen Salubris Pharmaceuticals
Osteoporosis Injections Segment by Type
Bone Formation Promoters
Bone Resorption Inhibitors
Osteoporosis Injections Segment by Application
Female
Male
Osteoporosis Injections Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Osteoporosis Injections market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Osteoporosis Injections and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Osteoporosis Injections.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Osteoporosis Injections manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Osteoporosis Injections by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Osteoporosis Injections in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Bone Formation Promoters
- Bone Resorption Inhibitors
Applications
- Female
- Male
Companies covered
- Alvogen
- Amgen
- Asahi Kasei Pharma
- Eli Lilly
- Novartis
- Pfizer
- Pharmanovia
- Radius Health
- Chengdu Easton Biopharmaceuticals
- Hunan Fangsheng Pharmaceutical
- Qilu Pharmaceutical
- Shanghai United Cell Biotechnology
- Shenzhen Salubris Pharmaceuticals
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Osteoporosis Injections Market Size (2021-2032)
- 2.2.2 Global Osteoporosis Injections Sales (2021-2032)
- 2.2.3 Global Osteoporosis Injections Market Average Price (2021-2032)
- 2.3 Osteoporosis Injections by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Bone Formation Promoters
- 2.3.3 Bone Resorption Inhibitors
- 2.4 Osteoporosis Injections by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Female
- 2.4.3 Male
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Osteoporosis Injections Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Osteoporosis Injections Sales (K Units) of Manufacturers (2021-2026)
- 3.3 Global Osteoporosis Injections Revenue of Manufacturers (2021-2026)
- 3.4 Global Osteoporosis Injections Average Price by Manufacturers (2021-2026)
- 3.5 Global Osteoporosis Injections Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Osteoporosis Injections, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Osteoporosis Injections, Product Type & Application
- 3.8 Global Manufacturers of Osteoporosis Injections, Established Date
- 3.9 Global Osteoporosis Injections Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Alvogen
- 4.1.1 Alvogen Company Information
- 4.1.2 Alvogen Business Overview
- 4.1.3 Alvogen Osteoporosis Injections Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Alvogen Osteoporosis Injections Product Portfolio
- 4.1.5 Alvogen Recent Developments
- 4.2 Amgen
- 4.2.1 Amgen Company Information
- 4.2.2 Amgen Business Overview
- 4.2.3 Amgen Osteoporosis Injections Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Amgen Osteoporosis Injections Product Portfolio
- 4.2.5 Amgen Recent Developments
- 4.3 Asahi Kasei Pharma
- 4.3.1 Asahi Kasei Pharma Company Information
- 4.3.2 Asahi Kasei Pharma Business Overview
- 4.3.3 Asahi Kasei Pharma Osteoporosis Injections Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Asahi Kasei Pharma Osteoporosis Injections Product Portfolio
- 4.3.5 Asahi Kasei Pharma Recent Developments
- 4.4 Eli Lilly
- 4.4.1 Eli Lilly Company Information
- 4.4.2 Eli Lilly Business Overview
- 4.4.3 Eli Lilly Osteoporosis Injections Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Eli Lilly Osteoporosis Injections Product Portfolio
- 4.4.5 Eli Lilly Recent Developments
- 4.5 Novartis
- 4.5.1 Novartis Company Information
- 4.5.2 Novartis Business Overview
- 4.5.3 Novartis Osteoporosis Injections Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Novartis Osteoporosis Injections Product Portfolio
- 4.5.5 Novartis Recent Developments
- 4.6 Pfizer
- 4.6.1 Pfizer Company Information
- 4.6.2 Pfizer Business Overview
- 4.6.3 Pfizer Osteoporosis Injections Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Pfizer Osteoporosis Injections Product Portfolio
- 4.6.5 Pfizer Recent Developments
- 4.7 Pharmanovia
- 4.7.1 Pharmanovia Company Information
- 4.7.2 Pharmanovia Business Overview
- 4.7.3 Pharmanovia Osteoporosis Injections Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Pharmanovia Osteoporosis Injections Product Portfolio
- 4.7.5 Pharmanovia Recent Developments
- 4.8 Radius Health
- 4.8.1 Radius Health Company Information
- 4.8.2 Radius Health Business Overview
- 4.8.3 Radius Health Osteoporosis Injections Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Radius Health Osteoporosis Injections Product Portfolio
- 4.8.5 Radius Health Recent Developments
- 4.9 Chengdu Easton Biopharmaceuticals
- 4.9.1 Chengdu Easton Biopharmaceuticals Company Information
- 4.9.2 Chengdu Easton Biopharmaceuticals Business Overview
- 4.9.3 Chengdu Easton Biopharmaceuticals Osteoporosis Injections Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Chengdu Easton Biopharmaceuticals Osteoporosis Injections Product Portfolio
- 4.9.5 Chengdu Easton Biopharmaceuticals Recent Developments
- 4.10 Hunan Fangsheng Pharmaceutical
- 4.10.1 Hunan Fangsheng Pharmaceutical Company Information
- 4.10.2 Hunan Fangsheng Pharmaceutical Business Overview
- 4.10.3 Hunan Fangsheng Pharmaceutical Osteoporosis Injections Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Hunan Fangsheng Pharmaceutical Osteoporosis Injections Product Portfolio
- 4.10.5 Hunan Fangsheng Pharmaceutical Recent Developments
- 4.11 Qilu Pharmaceutical
- 4.11.1 Qilu Pharmaceutical Company Information
- 4.11.2 Qilu Pharmaceutical Business Overview
- 4.11.3 Qilu Pharmaceutical Osteoporosis Injections Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 Qilu Pharmaceutical Osteoporosis Injections Product Portfolio
- 4.11.5 Qilu Pharmaceutical Recent Developments
- 4.12 Shanghai United Cell Biotechnology
- 4.12.1 Shanghai United Cell Biotechnology Company Information
- 4.12.2 Shanghai United Cell Biotechnology Business Overview
- 4.12.3 Shanghai United Cell Biotechnology Osteoporosis Injections Sales, Revenue and Gross Margin (2021-2026)
- 4.12.4 Shanghai United Cell Biotechnology Osteoporosis Injections Product Portfolio
- 4.12.5 Shanghai United Cell Biotechnology Recent Developments
- 4.13 Shenzhen Salubris Pharmaceuticals
- 4.13.1 Shenzhen Salubris Pharmaceuticals Company Information
- 4.13.2 Shenzhen Salubris Pharmaceuticals Business Overview
- 4.13.3 Shenzhen Salubris Pharmaceuticals Osteoporosis Injections Sales, Revenue and Gross Margin (2021-2026)
- 4.13.4 Shenzhen Salubris Pharmaceuticals Osteoporosis Injections Product Portfolio
- 4.13.5 Shenzhen Salubris Pharmaceuticals Recent Developments
5 Global Osteoporosis Injections Market Scenario by Region
- 5.1 Global Osteoporosis Injections Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Osteoporosis Injections Sales by Region: 2021-2032
- 5.2.1 Global Osteoporosis Injections Sales by Region: 2021-2026
- 5.2.2 Global Osteoporosis Injections Sales by Region: 2027-2032
- 5.3 Global Osteoporosis Injections Revenue by Region: 2021-2032
- 5.3.1 Global Osteoporosis Injections Revenue by Region: 2021-2026
- 5.3.2 Global Osteoporosis Injections Revenue by Region: 2027-2032
- 5.4 North America Osteoporosis Injections Market Facts & Figures by Country
- 5.4.1 North America Osteoporosis Injections Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Osteoporosis Injections Sales by Country (2021-2032)
- 5.4.3 North America Osteoporosis Injections Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Osteoporosis Injections Market Facts & Figures by Country
- 5.5.1 Europe Osteoporosis Injections Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Osteoporosis Injections Sales by Country (2021-2032)
- 5.5.3 Europe Osteoporosis Injections Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Osteoporosis Injections Market Facts & Figures by Country
- 5.6.1 Asia Pacific Osteoporosis Injections Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Osteoporosis Injections Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Osteoporosis Injections Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Osteoporosis Injections Market Facts & Figures by Country
- 5.7.1 South America Osteoporosis Injections Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Osteoporosis Injections Sales by Country (2021-2032)
- 5.7.3 South America Osteoporosis Injections Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Osteoporosis Injections Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Osteoporosis Injections Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Osteoporosis Injections Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Osteoporosis Injections Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Osteoporosis Injections Sales by Type (2021-2032)
- 6.1.1 Global Osteoporosis Injections Sales by Type (2021-2032) & (K Units)
- 6.1.2 Global Osteoporosis Injections Sales Market Share by Type (2021-2032)
- 6.2 Global Osteoporosis Injections Revenue by Type (2021-2032)
- 6.2.1 Global Osteoporosis Injections Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Osteoporosis Injections Revenue Market Share by Type (2021-2032)
- 6.3 Global Osteoporosis Injections Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Osteoporosis Injections Sales by Application (2021-2032)
- 7.1.1 Global Osteoporosis Injections Sales by Application (2021-2032) & (K Units)
- 7.1.2 Global Osteoporosis Injections Sales Market Share by Application (2021-2032)
- 7.2 Global Osteoporosis Injections Revenue by Application (2021-2032)
- 7.2.1 Global Osteoporosis Injections Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Osteoporosis Injections Revenue Market Share by Application (2021-2032)
- 7.3 Global Osteoporosis Injections Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Osteoporosis Injections Value Chain Analysis
- 8.1.1 Osteoporosis Injections Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Osteoporosis Injections Production Mode & Process
- 8.2 Osteoporosis Injections Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Osteoporosis Injections Distributors
- 8.2.3 Osteoporosis Injections Customers
9 Global Osteoporosis Injections Analyzing Market Dynamics
- 9.1 Osteoporosis Injections Industry Trends
- 9.2 Osteoporosis Injections Industry Drivers
- 9.3 Osteoporosis Injections Industry Opportunities and Challenges
- 9.4 Osteoporosis Injections Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst